

Scientific work performed thanks to the Bennink Foundation

Amsterdam, October 2023

Scientific Articles and Reviews:

2014

1. Garajová I, Le Large TY, Frampton AE, Rolfo C, Voortman J, Giovannetti E. **Molecular mechanisms underlying the role of microRNAs in the chemoresistance of pancreatic cancer.** *Biomed Res Int* 2014;2014:678401.

2015

1. Le Large TY, Meijer LL, Prado MM, Kazemier G, Frampton AE, Giovannetti E. **Circulating microRNAs as diagnostic biomarkers for pancreatic cancer.** *Exp Rev Mol Diagnostics*. 2015;15(12):1525-9.
2. Le Large TY, Frampton AE, Meijer LL, Stebbing J, Kazemier G, Giovannetti E. **Usefulness of Measuring microRNAs in Bile and Plasma for Pancreatic Ductal Adenocarcinoma Diagnosis.** *Am J Gastroenterol* 2015;110(5):768-9.

2016

1. Le Large TY, Mato Prado M, Krell J, Bijlsma MF, Meijer LL, Kazemier G, Frampton AE, Giovannetti E. **Bioinformatics reveals pancreatic cancer molecular subtypes specific to the tumor and microenvironment.** *Exp Rev Mol Diagnostics* 2016;16(7):733-6.
2. Caparello C,* Meijer LL,* Garajova I, Falcone A, Le Large TY, Funel N, Kazemier G, Peters GJ, Vasile E, Giovannetti E. **FOLFIRINOX and translational studies: Towards personalized therapy in pancreatic cancer.** *World J Gastroenterol*. 2016;22(31):6987-7005. (*equally contributed)
3. Meijer LL, Puik JR, Kazemier G, Peters GJ, Giovannetti E. **The hENT-1 Expression and Localization Predict Outcome to Adjuvant Gemcitabine in Resected Cholangiocarcinoma Patients.** *Oncologist*. 2016;21(12):e4.

2017

1. Le Large TYS, Bijlsma MF, Kazemier G, van Laarhoven HMW, Giovannetti E, Jimenez C.R. **Key biological processes driving metastatic spread of pancreatic cancer as identified by multi-omics studies.** *Semin Cancer Biol* 2017;44:153-169. <http://dx.doi.org/10.1016/j.semcan.2017.03.008>
2. Meijer LL, Frampton AE, Garajova I, Caparello C, Le Large TYS, Funel N, Vasile E, Stebbing J, Krell J, Kazemier G, Giovannetti E. **Circulating microRNAs as dynamic biomarkers of response to treatment with FOLFIRINOX combination therapy in advanced pancreatic ductal adenocarcinoma.** *Lancet* 2017;389, S68, [http://dx.doi.org/10.1016/S0140-6736\(17\)30464-6](http://dx.doi.org/10.1016/S0140-6736(17)30464-6)
3. Best MG,, Le Large TY, Meijer LL, Kazemier G, Giovannetti E et al. **Swarm Intelligence-Enhanced Detection of Non-Small-Cell Lung Cancer Using Tumor-Educated Platelets.** *Cancer Cell*. 2017;32(2):238-252.e9. doi: 10.1016/j.ccell.2017.07.004 doi: 10.1016/j.ccell.2017.07.004.
4. Puik JR,* Meijer LL,* Le Large TYS, Prado MM, Frampton AE, Kazemier G, Giovannetti E. **MicroRNA profiling for diagnosis, prognosis and stratification of cancer treatment in cholangiocarcinoma.** *Pharmacogenomics*. 2017;18(14):1343-1358. doi: 10.2217/pgs-2017-0010 (*equally contributed)

2018

1. Meijer LL, Alberga A, de Bakker JK, vd Vliet HJ, Le Large TYS, van Grieken NCT, de Vries, Daams F, Zonderhuis BM, Kazemier G et al. **Outcomes and treatment options for duodenal adenocarcinoma: A systematic review and meta-analysis.** *Annals of Surgical Oncology* 2018 Sep;25(9):2681-2692. doi: 10.1245/s10434-018-6567-6
2. Meijer LL, Kazemier G. **ASO Author Reflections: Current Treatment Options for Duodenal Adenocarcinoma-A Call for Collaborative Studies.** *Ann Surg Oncol*. 2018 Oct 16. doi: 10.1245/s10434-018-6896-5.
3. Le Large TYS, El Hassouni B, Kazemier G, Giovannetti E et al. **Multidrug-resistant transporter expression does not always result in drug resistance.** *Cancer Sci*. 2018 Oct;109(10):3360-3362. doi: 10.1111/cas.13756.
4. Choy ATF, Carnevale I, Coppola S, Meijer LL, Kazemier G, Zaura E, Deng D, Giovannetti E. **The microbiome of pancreatic cancer: from molecular diagnostics to new therapeutic approaches to overcome chemoresistance caused by metabolic inactivation of gemcitabine.** *Expert Rev Mol Diagn*. 2018 Nov 5:1-5. doi: 10.1080/14737159.2018.1544495.
5. Meijer LL, Garajová I, Caparello C, Le Large TY, Frampton AE, Vasile E, Funel N, Kazemier G, Giovannetti E. **Plasma miR-181a-5p Down-Regulation Predicts Response and Improved Survival After FOLFIRINOX in Pancreatic Ductal Adenocarcinoma.** *Ann Surg*. 2018 Nov 1. doi: 10.1097/SLA.0000000000003084.
6. Le Large TY, El Hassouni B, Funel N, Olive K, Kazemier, van Laarhoven HWM, Jimenez C, Bijlsma MF, Giovannetti E. **Proteomic analysis of gemcitabine resistant pancreatic cancer cells reveals microtubule-associated protein 2 to confer sensitivity to taxane treatment.** *Ther Adv Med Oncol*. 2019;11:1758835919841233. doi: 10.1177/1758835919841233.eCollection 2019.

2019

1. Meijer LL*, Puik JR*, Le Large TYS, Heger M, Dijk F, Funel N, Wurdinger T, Garajová I, van Grieken NCT, van de Wiel M, Giovannetti E, Kazemier G. **Unravelling the diagnostic dilemma of pancreatic head lesions: A panel of circulating microRNAs to diagnose distal cholangiocarcinoma.** (*equally contributed) *Cancers* 2019;11(8):1181. doi: 10.3390/cancers11081181.
2. El Hassouni B, Mantini G, Li Petri G, Capula M, Boyd L, Weinstein HNW, Vallés-Martí A, Kouwenhoven MCM, Giovannetti E, Westerman BA, Peters GJ; EORTC PAMM Group **To Combine or Not Combine: Drug Interactions and Tools for Their Analysis. Reflections from the EORTC-PAMM Course on Preclinical and Early-phase Clinical Pharmacology.** *Anticancer Res.* 2019;39(7):3303-3309. doi: 10.21873/anticancer.13472.
3. Leonetti A, Boyd L, Giuliani J, Giovannetti E, Garajová I, on behalf of the EORTC-PAMM group. **Light and shadow on innovative clinical trial designs: Reflections from the EORTC-PAMM Course on "Preclinical and Early-phase Clinical Pharmacology"** *Expert Rev Clin Pharmacol* 2019;12(11):1033-1036. doi: 10.1080/17512433.2019.1683446.
4. Meijer LL, Zwart ES, Brandt BW, Mebius R, Deng D, Giovannetti E, Zaura E, Kazemier G. **Tumor microbiome: Pancreatic cancer and duodenal fluids contain multitudes, ...but do they contradict themselves?** *Crit Rev Oncol Hematol.* 2019 Dec;144:102824. doi: 10.1016/j.critrevonc.2019.102824. Epub 2019 Nov 2.

2020

1. Le Large TYS, Meijer LL, Paleckyte R, Boyd LNC, Kok B, Wurdinger T, Schelfhorst T, Piersma SR, Pham TV, van Grieken NCT, Zonderhuis BM, Daams F, van Laarhoven HWM, Bijlsma MF, Jimenez CR, Giovannetti E, Kazemier G. **Combined expression of plasma thrombospondin-2 and CA19-9 for diagnosis of pancreatic cancer and distal cholangiocarcinoma – A proteome approach** *Oncologist* 2020;25(4):e634-e643. doi: 10.1634/theoncologist.2019-0680.
2. El Hassouni B, Granchi C, Vallés-Martí A, Supadmanaba IGP, Bononi G, Tuccinardi T, Funel N, Jimenez CR, Peters GJ, Giovannetti E, Minutolo F. **The dichotomous role of the glycolytic metabolism pathway in cancer metastasis: Interplay with the complex tumor microenvironment and novel therapeutic strategies.** *Semin Cancer Biol.* 2020 Feb;60:238-248.
3. Mantini G, Vallés AM, Le Large TYS, Capula M, Funel N, Pham TV, Piersma SR, Kazemier G, Bijlsma MF, Giovannetti E, Jimenez CR. **Co-expression analysis of pancreatic cancer proteome reveals biology and prognostic biomarkers.** *Cell Oncol (Dordr).* 2020 Aug 29. doi: 10.1007/s13402-020-00548-y. Online ahead of print.
4. Le Large TY, Mantini G, Meijer LL, Pham TV, Funel N, van Grieken NC, Kok B, Knol J, van Laarhoven HW, Piersma SR, Jimenez CR, Kazemier G, Giovannetti E, Bijlsma MF. **Microdissected pancreatic cancer proteomes reveal tumor heterogeneity and therapeutic targets.** *JCI Insight.* 2020 Aug 6;5(15):e138290. doi: 10.1172/jci.insight.138290
5. Boyd LNC, Peters GJ, Kazemier G, Giovannetti E. **NUC-1031 in biliary tract cancer: from bench to bedside and back?** *Cancer Chemother Pharmacol.* 2020 Jun;85(6):1011-1014. doi: 10.1007/s00280-020-04080-6. Epub 2020 May 31.
6. Meijer LL, Strijker M, de Bakker JK, Toennaer JGJ, Zonderhuis BM, van der Vliet HJ, Wilmink H, Verheij J, Daams F, Busch OR, van Grieken NCT, Besselink MG, Kazemier G. **Clinical outcome of patients with duodenal adenocarcinoma and intestinal-type papilla of Vater adenocarcinoma.** *World J Gastrointestinal Oncol* 2020
7. Che PP, Gregori A, Firuzi O, Dahele M, Sminia P, Peters GJ, Giovannetti E. **Pancreatic cancer resistance conferred by stellate cells: looking for new preclinical models.** *Exp Hematol Oncol.* 2020;9:18.
8. Che PP, Gregori A, Peters GJ, Dahele M, Sminia P, Giovannetti E. **Comment on: Targeting the HGF/c-MET pathway in advanced pancreatic cancer: a key element of treatment that limits primary tumour growth and eliminates metastasis.** *Br J Cancer.* 2020; 123(9):1464-1465.

2021

1. Le Large TYS, Bijlsma MF, El Hassouni B, Mantini G, Lagerweij T, Henneman AA, Funel N, Kok B, Pham TV, de Haas R, Morelli L, Knol JC, Piersma SR, Kazemier G, van Laarhoven HWM, Giovannetti E,* Jimenez CR.* **Focal adhesion kinase inhibition synergizes with nab-paclitaxel to target pancreatic ductal adenocarcinoma.** *J Exp Clin Cancer Res.* 2021;40(1):91. (*equally contributed)
2. Boyd LNC, Andini KD, Peters GJ, Kazemier G, Giovannetti E. **Heterogeneity and plasticity of cancer-associated fibroblasts in the pancreatic tumor microenvironment.** *Semin Cancer Biol.* 2021 doi: 10.1016/j.semcancer.2021.03.006. Online ahead of print.
3. Rodriguez E, Boelaars K, Brown K, Eveline Li RJ, Kruijssen L, Bruijns SCM, van Ee T, Schetters STT, Crommentuijn MHW, van der Horst JC, van Grieken NCT, van Vliet SJ, Kazemier G, Giovannetti E, Garcia-Vallejo JJ, van Kooyk Y. **Sialic acids in pancreatic cancer cells drive tumour-associated macrophage differentiation via the Siglec**

receptors **Siglec-7 and Siglec-9**. *Nat Commun*. 2021 Feb 24;12(1):1270. doi: 10.1038/s41467-021-21550-4.PMID: 33627655

4. Le Large TYS, Boyd LNC, Kazemier G, Giovannetti E. **The proteomic landscape of pancreatic ductal adenocarcinoma liver metastases identifies molecular subtypes and associations with clinical response - Letter**. *Clin Cancer Res*. 2021;27(14):4126. doi: 10.1158/1078-0432.CCR-21-0775.
5. Pecoraro C, Faggion B, Balboni B, Carbone D, Peters GJ, Diana P, Assaraf YG, Giovannetti E. **GSK3 β as a novel promising target to overcome chemoresistance in pancreatic cancer**. *Drug Resist Updat*. 2021 Sep;58:100779. doi: 10.1016/j.drug.2021.100779. Epub 2021 Aug 12.PMID: 34461526
6. Casolino R, Biankin AV; PanCaCovid-19 Study Group. **Impact of COVID-19 on Pancreatic Cancer Research and the Path Forward**. *Gastroenterology*. 2021 Aug 10:S0016-5085(21)03348-5. doi: 10.1053/j.gastro.2021.06.080. Online ahead of print.PMID: 34389342

2022

1. Boyd LNC, Ali M, Kam L, Puik JR, Rodrigues SMF, Zwart ES, Daams F, Zonderhuis BM, Meijer LL, Le Large TYS, Giovannetti E, van Laarhoven HWM, Kazemier G. **The Diagnostic Value of the CA19-9 and Bilirubin Ratio in Patients with Pancreatic Cancer, Distal Bile Duct Cancer and Benign Periampullary Diseases, a Novel Approach**. *Cancers (Basel)*. 2022 Jan 11;14(2):344. doi: 10.3390/cancers14020344.
2. Comandatore A, Immordino B, Balsano R, Capula M, Garajová I, Ciccolini J, Giovannetti E, Morelli L. **Potential Role of Exosomes in the Chemoresistance to Gemcitabine and Nab-Paclitaxel in Pancreatic Cancer**. *Diagnostics (Basel)*. 2022 Jan 23;12(2):286. doi: 10.3390/diagnostics12020286.
3. Rodriguez E, Boelaars K, Brown K, Madunić K, van Ee T, Dijk F, Verheij J, Li RJE, Schetters STT, Meijer LL, Le Large TYS, Driehuis E, Clevers H, Bruijns SCM, O'Toole T, van Vliet SJ, Bijlsma MF, Wuhrer M, Kazemier G, Giovannetti E, Garcia-Vallejo JJ, van Kooyk Y. **Analysis of the glyco-code in pancreatic ductal adenocarcinoma identifies glycan-mediated immune regulatory circuits**. *Commun Biol*. 2022 Jan 11;5(1):41. doi: 10.1038/s42003-021-02934-0.
4. Costamagna A, Natalini D, Camacho Leal MDP, Simoni M, Gozzelino L, Cappello P, Novelli F, Ambrogio C, Defilippi P, Turco E, Giovannetti E, Hirsch E, Cabodi S, Martini M. **Docking Protein p130Cas Regulates Acinar to Ductal Metaplasia During Pancreatic Adenocarcinoma Development and Pancreatitis**. *Gastroenterology*. 2022 Apr;162(4):1242-1255.e11. doi: 10.1053/j.gastro.2021.12.242. Epub 2021 Dec 17. PMID: 34922945
5. Garajová I, Balsano R, Donati V, Gnetti L, Capula M, Leonardi F, Valle RD, Ravaioli M, Gelsomino F, Giovannetti E. **Implications of Perineural Invasion on Disease Recurrence and Survival After Pancreatectomy for Pancreatic Head Ductal Adenocarcinoma**. *Ann Surg*. 2022 Aug 1;276(2):e136-e137. doi: 10.1097/SLA.0000000000005275. Epub 2021 Nov 11. PMID: 35129485
6. Comandatore A, Balsano R, Immordino B, Arguedas D, Capula M, Baglio SR, Garajová I, Malapelle U, Morelli L, Giovannetti E. **"Depart from evil, and do good": Turning Axl from uncontrolled tumorigenic gene to biomarker for early detection of pancreatic cancer**. *Crit Rev Oncol Hematol*. 2022 May;173:103659. doi: 10.1016/j.critrevonc.2022.103659. Epub 2022 Apr 6. PMID: 35398264
7. In 't Veld SGJG, et al. **Detection and localization of early- and late-stage cancers using platelet RNA**. *Cancer Cell*. 2022 Sep 12;40(9):999-1009.e6. doi: 10.1016/j.ccell.2022.08.006. Epub 2022 Sep 1. PMID: 36055228
8. Puik JR, Swijnenburg RJ, Kazemier G, Giovannetti E. **Novel Strategies to Address Critical Challenges in Pancreatic Cancer**. *Cancers (Basel)*. 2022 Aug 25;14(17):4115. doi: 10.3390/cancers14174115. PMID: 36077652
9. Boyd LNC, Ali M, Leeflang MMG, Treglia G, de Vries R, Le Large TYS, Besselink MG, Giovannetti E,* van Laarhoven HWM, Kazemier G. **Diagnostic accuracy and added value of blood-based protein biomarkers for pancreatic cancer: A meta-analysis of aggregate and individual participant data**. *EClinicalMedicine*. 2022; 55:101747

2023

1. Gregori A, Bergonzini C, Capula M, Mantini G, Khojasteh-Leylakoochi F, Comandatore A, Khalili-Tanha G, Khooei A, Morelli L, Avan A, Danen EH, Schmidt T, Giovannetti E. **Prognostic Significance of Integrin Subunit Alpha 2 (ITGA2) and Role of Mechanical Cues in Resistance to Gemcitabine in Pancreatic Ductal Adenocarcinoma (PDAC)**. *Cancers* 2023, 15(3), 628
2. Jiang Y, Donati V, Peters GJ, Giovannetti E, Deng DM. Yialing. Fungal mycobiome-mediated immune response: a non-negligible promoter in pancreatic oncogenesis and chemoresistance. *Cancer Drug Resist* in press
3. Boyd LNC, Ali M, Puik JR, Meijer LL, Le Large TYS, van Laarhoven HWM, Giovannetti E, Kazemier G. **hENT1 expression predicts response to gemcitabine and nab-paclitaxel in advanced pancreatic ductal adenocarcinoma (PDAC)**. *Clin Cancer Res*, 29(15):2944
4. De Santis MC, Gozzelino L, Margaria JP, Costamagna A, Ratto E, Gulluni F, Di Gregorio E, Mina E, Lorito N, Bacci M, Lattanzio R, Sala G, Cappello P, Novelli F, Giovannetti E, Vicentini C, Andreani S, Delfino P, Corbo V,

- Scarpa A, Porporato PE, Morandi A, Hirsch E, Martini M. **Lysosomal lipid switch sensitises to nutrient deprivation and mTOR targeting in pancreatic cancer.** *Gut* 2023; 72(2):360-371.
5. Rebelo R, Xavier CPR, Giovannetti E, Vasconcelos MH. **Fibroblasts in pancreatic cancer: molecular and clinical perspectives.** *Trends Mol Med* 2023;29(6):439-453.
 6. Vahabi M, Dehni B, Antomas I, Giovannetti E, Peters GJ. **Targeting miRNA and using miRNA as potential therapeutic options to bypass resistance in pancreatic ductal adenocarcinoma.** *Cancer Met Rev.* Online ahead of print.
 7. Boyd LNC, Ali M, Comandatore A, Garajova I, Kam L, Puik JR, Rodrigues SMF, Meijer LL, Le Large TYS, Besselink M, Morelli L, Frampton A, van Laarhoven HWM, Giovannetti E, Kazemier G. **Development and validation of a prediction model for early-stage pancreatic cancer using routinely measured blood biomarkers.** *JAMA Netw Open.* 2023;6(8):e2331197

Book Chapters:

1. Garajová I, Le Large TY, Giovannetti E, Kazemier G, Biasco G, Peters GJ. **The role of microRNAs in resistance to current pancreatic cancer treatment: translational studies and basic protocols for extraction and PCR analysis.** *Methods Mol Biol.* 2016;1395:163-87. *Chapter 10.*
2. Meijer LL, Puik JR, Le Large TYS, Frampton AE, Kazemier G, Giovannetti E. **Modification of drug response by microRNAs and microRNA polymorphisms.** *Royal Society of Chemistry Book: MicroRNAs in Diseases and Disorders: Emerging Therapeutic Targets, edited by Dr Philip Peplow. (in press) (*equally contributed)*
3. Oczko-Wojciechowska M, Giovannetti E. **ESMO Handbook of Targeted Therapies and Precision Oncology. Chapter 2: Molecular Techniques in Precision Oncology.** *Published: September 2022 Online - ESMO -European Society of Medical Oncology website at: <https://oncologypro.esmo.org/education-library/esmo-handbooks/targeted-therapies-and-precision-oncology>*

Congress Abstracts / Posters / Presentations:

2014

1. Oral presentation, Wetenschapsdag Chirurgie VUmc, November 2014, Tessa Le Large

2015

1. Poster presentation, Science Exchange Day VUmc, September 2015, Tessa Le Large
2. Poster presentation, Science Exchange Day VUmc, September 2015, Laura Meijer
3. Oral presentation, Wetenschapsdag Chirurgie, November 2015, Tessa Le Large
4. Oral presentation, Wetenschapsdag Chirurgie, September 2015, Laura Meijer

2016

1. Oral presentation, EORTC-PAMM Congress, Antwerp, Belgium, February 2016, Tessa Le Large
2. Invited speaker, EORTC-PAMM Congress, Antwerp, Belgium, February 2016, Elisa Giovannetti
3. Oral Presentation, EORTC-PAMM Congress, Antwerp, Belgium, February 2016, Laura Meijer
4. Oral Presentation, IHPBH congress, San Paolo, Brazil, April 2016, Laura Meijer
5. Poster Presentation, IHPBH congress, San Paolo, Brazil, April 2016, Tessa Le Large
6. Poster Presentation, IHPBH congress, San Paolo, Brazil, April 2016, Babs Zonderhuis
7. Oral Presentation, Chirurgendagen, Veldhoven, May 2016, Tessa Le Large
8. Oral Presentation, AISP congress, Rome, Italy, September 2016, Chiara Caparello
9. Oral presentation, Wetenschapsdag Chirurgie VUmc, November 2016, Jisce Puik
10. Oral presentation, Wetenschapsdag Chirurgie VUmc, November 2016, Laura Meijer

2017

1. Poster presentation, AACR, Washington DC, US, April 2017, Tessa Le Large
2. Oral Presentation, E-AHPBA congress, Mainz, Germany, May 2017 Laura Meijer
3. Poster Presentation, E-AHPBA congress, Mainz, Germany, May 2017 Tessa Le Large
4. Oral Presentation, E-AHPBA congress, Mainz, Germany, May 2017 Babs Zonderhuis
5. Oral Presentation, EPC congress, Budapest, Hungary, June 2017, Laura Meijer
6. Poster Presentation, EPC congress, Budapest, Hungary, June 2017, Tessa Le Large
7. Invited lecture, ESMO Congress, Madrid, Spain, September 2017, Elisa Giovannetti
8. Invited lecture, MATD Congress, Paris, France, September 2017, Elisa Giovannetti
9. Oral Presentation, AISP congress, Milano, Italy, October 2017, Ingrid Garajova

2018

1. Oral presentation, EORTC-PAMM Congress, Roma, Italy, February 2016, Ilaria Carnevale
2. Oral presentation, CCA retraite, Noordwijkerhout, February 2018, Laura Meijer
3. Oral presentation, CCA retraite, Noordwijkerhout, February 2018, Ilaria Carnevale

4. Invited lecture, 3rd International course of endovascular oncology, Pesaro, Italy, March 2018, Elisa Giovannetti
5. Invited lecture, Italian-French Erasmus Intensive Course in Oncology organized in collaboration with European Master of Genetics - University Paris7-Paris5, Firenze, Italy, March 2018, Elisa Giovannetti
6. Poster Presentation, AACR congress, Chicago, US, April 2018, Tessa Le Large
7. Poster Presentation, AACR congress, Chicago, US, April 2018, Laura Meijer
8. Poster Presentation, AACR congress, Chicago, US, April 2018, Jisce Puik
9. Oral Presentation, Chirurgendagen, Veldhoven, May 2018, Tessa Le Large
10. Oral Presentation, Chirurgendagen, Veldhoven, May 2018, Laura Meijer
11. Poster Presentation, EPC 2018, Berlin, Germany 2018, Tessa Le Large
12. Oral Presentation, IHPBA, Geneva 2018, Laura Meijer
13. Oral Presentation, IHPBA, Geneva 2018, Tessa Le Large
14. Oral Presentation, AISP congress, Roma, Italy, October 2018, Ilaria Carnevale

2019

1. Poster presentation, EORTC-PAMM Congress, Verona, Italy, February 2019, Lenka Boyd
2. Poster presentation, EORTC-PAMM Congress, Verona Italy, February 2019, Ingrid Garajová
3. Poster presentation, CCA retraite, Noordwijkerhout, NL, February 2019, Lenka Boyd
4. Poster Presentation, AACR congress, Boston, US, April 2019, Lenka Boyd
5. Poster presentation, OOA retraite, Rennesse, NL, October 2019, Lenka Boyd
6. Oral presentation, Wetenschapsdag Chirurgie VUmc, November 2019, Lenka Boyd

2020

1. Poster presentation, EORTC-PAMM Congress, Stockholm, Sweden, January 2020, Giulia Mantini
2. Poster Presentation, AACR congress (online), July 2020, Giulia Mantini
7. Poster presentation, EPC 2020 (online), June 2020, Lenka Boyd
8. Invited lecture, International Society of Liquid Biopsy congress (online), 2020, Elisa Giovannetti
3. Oral presentation, EPC 2020 (online), June 2020, Giulia Mantini
9. Oral presentation, EORTC-PAMM Congress, Stockholm, Sweden, January 2020, Mjriam Capula
10. Oral presentation, AISP congress, Verona, Italy, September 2020, Giulia Mantini
11. Oral presentation, AISP congress, Verona, Italy, September 2020, Mjriam Capula

2021

1. Oral presentation, EORTC-PAMM Congress, Brussels (online), April 2021, Pei Pei Che
2. Oral presentation, EPC 2020 (online), June 2020, Andrea Valles
3. Poster Presentation and short Oral communication, EPC 2021, Verona (online) June 2021, Lenka Boyd
4. Poster Presentation and short Oral communication, EPC 2021, Verona (online) June 2021, Mjriam Capula
5. Poster Presentation, EPC 2021, Verona (online) June 2021, Giulia Mantini
6. Invited lecture at the meeting "Response and Resistance in Cancer Therapy", University of Kent campus, Canterbury, UK, 15-17 June 2020, postponed to September 5-6, 2021
7. Invited lecture "EORTC GITCG Pancreatic Cancer Think Tank: EORTC PAMM - ongoing activities/ideas for collaborations", Brussels - online, 16 July 2021, Elisa Giovannetti
8. EACR sponsored Invited lecture at the meeting "Response and Resistance in Cancer Therapy", University of Kent campus, Canterbury, UK, September 5-6, 2021, Elisa Giovannetti
9. Oral presentation, AISP congress, Verona, Italy, September 2021, Annalisa Comandore
10. Invited lecture at the 2nd Congress of the International Society for the Study of Pleura and Peritoneum (ISSPP), Rome University of the Sacred Heart, Italy, 7-8 of October 2021. The ISSPP 2021 congress, endorsed by the European Society of Surgical Oncology (ESSO), Elisa Giovannetti
11. Invited lecture "Actionable mutations" at the "Annual (Virtual) Symposium on Precision Medicine", Auna - Peruvian network of health centers, November 2021, Elisa Giovannetti
12. Invited lecture "(Mechano)pharmacology approaches to fight pancreatic cancer chemoresistance?" at the Hybrid Workshop: 'Cancer in a Physical Context: From Understanding to Therapeutics' Lorentz Center, Leiden, The Netherlands, December 2021, Elisa Giovannetti

2022

1. Oral presentation, American Pancreas Club, San Diego, May 2022, Annalisa Comandore
2. Oral presentation, Medical Oncology, May 2022, Jisce Puik
3. Oral presentation, EPC 2022 (online), June 2022, Annalisa Comandore
4. Poster presentation, CCA retraite, Noordwijkerhout, NL, July 2022, Mahsoem Ali
5. Poster presentation, CCA retraite, Noordwijkerhout, NL, July 2022, Jisce Puik
6. Oral Presentation, AISP meeting, Bergamo, September 2022, Benoit Immordino
7. Invited lecture "c-Met in pancreatic cancer", EORTC GITCG Pancreatic Cancer Task Force, Brussels – online, Elisa Giovannetti

8. Invited lecture "Biological underpinnings of pancreatic cancer chemoresistance" EORTC-PAMM
9. Oral presentation, Wetenschapsdag Chirurgie Amsterdam UMC, October, Jisce Puik
10. Oral presentation, EORTC-PAMM meeting, December 2022, Jisce Puik

2023

1. Invited lecture EMBO meeting: Tumour Metabolism: Current Understanding and Opportunities for Novel Drug Discovery Amit University, Noida, India, 28-31 March 2023
2. Invited lecture, meeting of the COST Action TRANSPAN, Heidelberg, April 2023
3. Poster presentation at the E-AHPBA conference, Lyon, France, June 2023, Jisce Puik
4. Invited lecture 19th World Congress of Basic & Clinical Pharmacology, Glasgow, July 2023
5. Oral presentation, EPC 2023 July 2023, Mjriam Capula
6. Oral presentation, CCA conference, Noordwijkerhout, NL, July 2023, Jisce Puik
7. Keynote invited lecture "Clinical significance of key effectors of the glycolytic pathway and perspective therapeutic agents exploiting tumor glycolysis" in the Meeting celebrating the 50th years of the Research Department CITO Smart, Marseille 11-13 July 2023
8. Invited lecture at congress "NEXT Oncology. Supporting Oncology through Innovation", Milan, Italy 9th & October 10th 2023
9. Oral presentation, Wetenschapsdag Chirurgie Amsterdam UMC, October 2023, Jisce Puik
10. Oral presentation, Medical Oncology Amsterdam UMC, October 2023, Jisce Puik

Grants awarded / applications:

2016

1. Travel grant EORTC-PAMM meeting, Antwerp, awarded February 2016, Young Investigator Tessa Le Large
2. Travel grant EORTC-PAMM meeting, Antwerp, awarded February 2016, Young Investigator Laura Meijer
3. Lisa Waller Hayes Foundation Grant, awarded April 2016, Tessa Le Large
4. Proof-of-Concept CCA grant, June 2016 "Bench-to-bedside studies on the role of exosomal uptake for the individualized selection of effective drugs against metastatic pancreatic cancer"
5. Best presentation Award among young investigators, AISP congress, Roma, September 2016, Chiara Caparello

2017

1. KWF grant, "Development and validation of phosphoproteomics to support personalized treatments in pancreatic cancer"
2. KWF grant, "Evaluation of tumor-educated platelet profiles for screening and follow-up of pancreatic cancer"
3. CCA grant, April 2017 "The microbiome of pancreatic cancer: a correlation between bacteria and pancreatic cancer?"
4. Travel grant EPC meeting, Budapest, Hungary, June 2017, Tessa Le Large
5. Travel grant EPC meeting, Budapest, Hungary, June 2017, Laura Meijer
6. Travel grant E-AHPBA meeting Mainz 2017, Laura Meijer
7. NWO Visitor's Travel grant 2017 for Prof. Omidreza Firuzi (Shiraz University, Iran), "Targeting C-met and related signaling pathways in three-dimensional co-cultures of primary pancreatic cancer and stellate cells"
8. Best Honor Program student, Jisce Puik
9. Nijbakker-Morra Studentenkrijs, Jisce Puik

2018

1. CCA Next Best Pitch Award, January 2018, Laura Meijer
2. EORTC-PAMM meeting 2018, February 2018, Roma, Oral Presentation grant, Ilaria Carnevale
3. American Association for Cancer Research, AACR-Warner Fund Scholar-in-Training Award, April 2018, Jisce Puik
4. Fondazione Pisana per la Scienza Onlus grant 2018, Elisa Giovannetti
5. Collaboration with University Hospitals of Florence and Pisa for the FAS-2018 grant application on "Exploiting ion channels and transporters for personalized therapeutic strategies in pancreatic and colorectal cancer"

2019

1. CCA Proof-of-concept grant, February 2019 "A mechanopharmacology approach to overcome chemoresistance in pancreatic cancer", in collaboration with Prof. W. Crielaard (ACTA)

2020

1. Horizon 2020 Marie Skłodowska-Curie RISE grant ALISE (Antibody Light-Induced Selectivity Enhancement for pancreatic cancer drugs)
2. KWF grant in collaboration with MCBI "The glycode in pancreas cancer: immune-suppressive signatures, novel opportunities for diagnosis and therapy"
3. PANOMICS grant in collaboration with University of Pisa on new preclinical models for omics analysis of pancreatic cancer

2021

1. AIRC Investigator grant "Studies on exosomes and translational research in pancreatic cancer"
2. KWF grant in collaboration with Pathology, "Exploiting the pivotal role of exosomal-AXL in liver colonization for the individualized selection of effective drugs against metastatic pancreatic cancer"
3. Rotary Global grant (Italy/The Netherlands) for the project "Bench-to-bedside studies for the individualized selection of effective drugs against pancreatic cancer",
4. STRATAGEM COST Action 17104 <https://stratagem-cost.eu>. Identification of new biomarkers and therapeutic targets for MDR tumours

2022

- 1) PanCan Award, Pancreas Club 2022 San Diego 2022, Annalisa Comandatore
- 2) Young Investigator Travel Award, *EPC* meeting, Kiev - online 2022, Annalisa Comandatore
- 3) Oral Presentation Award, *AISP meeting*, Bergamo, 2022, Benoit Immordino
- 4) Pancreatic Cancer Europe Travel grant 2022, Mjriam Capula
- 5) COST Action CA21116 TRANSPAN "Identification of biological markers for prevention and translational medicine in pancreatic cancer"

2023

- 1) Lisa Waller Hayes grant 2023, Pei Pei Che
- 2) AIRC Bridge Grant collaboration with by Dr. Enza Lonardo "Targeting the cancer (stem) cells – tumor microenvironment crosstalk to improve pancreatic cancer prognosis"
- 3) KWF grant in collaboration with ACTA, "Bugging chemoresistance": bench-to-bedside studies to unravel and target the mechanisms underlying bacteria-induced chemoresistance in pancreatic cancer